Recombinant allergens for the diagnosis of type I allergy;Rekombinante allergene in der diagnose der typ I allergie

LaboratoriumsMedizin

Volumn 26, Issue 3-4, 2002, Pages 120-129

  Westritschnig, Kerstin ^a   Kraft, D ^a   Valenta, R ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Allergen extracts; Co sensitization; Component resolved diagnosis (CRD); Cross sensitization; Diagnosis; Recombinant allergens; Specific immunotherapy; Type I allergy

Indexed keywords

ALLERGEN; CALCIUM; IMMUNOGLOBULIN E; POLLEN ANTIGEN; RECOMBINANT PROTEIN;

CROSS ALLERGY; CROSS REACTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; IN VITRO STUDY; PREDICTION; REVIEW; SENSITIZATION; TREATMENT PLANNING;

EID: 0036227214     PISSN: 03423026     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1439-0477.2002.02039.x     Document Type: Review

References (81)

1. Biology and genetics of atopic diseases
2. The germless theory of allegic disease: Revisiting the hygiene hypothesis
3. Dimeric immunglobulin E serves as a unit signal for mast cell degranulation
4. Fc epsilon RI on antigen-presenting cells
5. IgE-mediated allergen presentation via Fc epsilon RI on antigen-presenting cells
6. Allergen immunotherapy: Therapeutic vaccines for allergic diseases. A WHO position paper
7. Immunological changes associated with allergen immunotherapy
8. Serological evidence on immunity with co-exisiting sesnitization in a type of human allergy, hay fever
9. Immunological studies of pollinosis: I. The presence of two antibodies related to the same pollen antigen in the serum of treated hay fever patients
10. Immunological studies of pollinosis. IV. The relationship between thermostable antibody in the circulation and clinical immunity
11. Measurement of IgG blocking antibodies: Development and application of a radioimmunoassay
12. Measurement of IgG blocking antibodies by interference in the radioallergosorbent test
13. Serologic aspects of IgG4 antibodies I. Prolonged immunization results in an IgG4-restricted response
14. A quantitative in vitro study of the chromatographic distribution and immunoglobulin characteristics of human blocking antibodies
15. Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy
16. Immunotherpy decreases antigen-induced eosinophil migration into the nasal cavity
17. Changes in nasal metachromatic cells during allergen immunotherapy
18. Nasal challenge with ragweed in hay fever patients: Effect of immunotherapy
19. Generation of antigen-specific surpressor cells during allergy desensitization
20. + T cells from allergic individuals
21. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-γ secretion in specific allergen-stimulated T cell cultures
22. Immunological changes during specific immunotherapy of grass pollen allergy: Reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Ph1 p 1, a major grass pollen allergen
23. Role of interleukin 10 in specific immunotherapy
24. Recombinant allergens for diagnosis and therapy of allergic diseases
25. Recombinant allergens
26. The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT)
27. Recombinant allergens
28. Genetically engineered and synthetic allergen derivatives; candidates for vaccination against type I allergy
29. Genetically engineered plant allergens with reduced anaphylactic activity
30. Synthetic and genetically engineered allergen derivatives for specific immunotherapy of type I allergy
31. Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1. Results obtained with a mix of two recombinant Bet v 1 fragments and rBet v 1 trimer in a Swedish population before the birch pollen season
32. Clinical evaluation of genetically engineered hypoallergenic rBet v 1 derivatives by skin prick and intradermal testing: Results obtained in a French population
33. Genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1, induces less eosinophilic activity in skin chamber fluids collected from birch pollen allergic patients than rBet v 1 wild type
34. Reduced in vivo allergenicity of Bet v 1d isoform, a natural component of birch pollen
35. Recombinant allergens for immunoblot diagnosis of tree-pollen allergy
36. Diagnosis of grass pollen allergy with recombinant timothy grass (Phleum pratense) pollen allergens
37. Identification of multiple T-cell epitopes on Bet v 1 the major birch pollen allergen using specific T cell clones and overlapping peptides
38. Induction of specific histamine release from basophils with purified natural and recombinant birch pollen allergens
39. Induction of IgE antibodies in mice with recombinant grass pollen allergens
40. Induction of IgE antibodies with predefined specifity in rhesus monkeys with recombinant birch pollen allergens, Bet v 1 and Bet v 2
41. Induction of IgE antibodies in mice and rhesus monkeys with recombinant birch pollen allergens; different allergenicity of Bet v 1 and Bet v 2
42. Diagnosic value of recombinant Aspergillus fumigatus allergen I for skin testing and serology
43. 2 from honeybee venom is similar
44. Serological and skin-test diagnosis of birch pollen allergy with recombinant Bet v 1, the major birch pollen allergen
45. Skin testing with recombinant allergens rBet v 1 and birch profilin, rBet v 2: Diagnostic value for birch pollen and associated allergies
46. In vivo biological activity of recombinant Der p 2 allergen of house dust mite
47. Cloning, expression and immunological characterization of recombinant Lolium perenne allergen, Lol p 2
48. False-positive skin prick test responses to commercially available dog dander extracts caused by contamination with house dust mite (Dermatophagoides pteronyssinus) allergens
49. The spectrum of olive pollen allergens
50. Towards defining the full spectrum of important house dust mite allergens
51. Recombinant allergens for diagnosis and therapy of allergic disease
52. Structure and biology of stinging insect venom allergens
53. Microarrayed allergen molecules: Diagnostic gatekeepers for allergy treatment
54. Prevalence of atopy and pollinosis in the adult population of Switzerland (SALPADIA study). Swiss study on air pollution and lung diseases in adults
55. Recombinant birch pollen allergens (rBet v 1, rBet v 2) contain most of the IgE epitopes present in birch, elder, hornbeam, hazel, and oak pollen. A quantitative IgE inhibition study using sera from different populations
56. The spectrum of olive pollen allergens
57. IgE antibodies to recombinant pollen allergens (Phl p 1, Phl p 2, Phl p 5, and Bet v 2) account for a high percentage of grass pollen-specific IgE
58. Molecular and biochemical classification of plant-derived food allergens
59. Identification of profilin as a novel allergen: IgE autoreactivity in sensitized individuals
60. Profilifis constitute a novel familiy of functional plant pan-allergens
61. Purification and characterization of an allergen from celery immunolgical related to an allergen present in several other plant species. Identification as a profilin
62. Profilin is a cross-reactive allergen in pollen and vegetable foods
63. Different profiles in specific IgE to rBrt v 1 and rBet v 2 in patients allergic to birch pollenfrom six countries
64. Development of new IgE reactivities to allergenic components in pollen extracts during specific immunotherapy studied with immunoblotting and the Pharmacia CAP system
65. Calcium-binding allergen: From plants to man
66. Calcium-binding proteins in Type I allergy: Elicitors and vaccines
67. Molecular, structural, and immunological relationships between different families of recombinant calcium-binding pollen allergens
68. Recombinant allergens for immunoblot diagnosis of tree-pollen allergy
69. The immunological relationship of epitopes on major tree pollen allergens
70. Purification, characterization and N-terminal amino acid sequence of a new major allergen from European chestnut pollen, Cas s 1
71. Identification of allergens in fruits and vegetables: IgE cross-reactivities with the important birch pollen allergens Bet v 1 and Bet v 2 (birch profilin)
72. Identification of common allergenic structures in hazel pollen and hazelnuts: A possible explanation for sensitivity to hazelnuts in patients allergic to tree pollen
73. Molecular characterization of Dau c 1, the Bet v 1 homologous protein from carrot and its cross-reactivity with Bet v 1 and Api g 1
74. Molecular charactrization of Api g 1, the major allergen of celery (Apium graveolens), and its immunological and structural relationships to a group of 17 kDa tree pollen allergens
75. Allergic cross-reactivity made visible: Solution structure of the major cherry allergen Pru av 1
76. Cloning and sequencing of Mal d 1, the major allergen from apple (Malus domestica), and its immunological relationship to Bet v 1, the major birch pollen allergen
77. Immunotherapy with partially purified and standardized tree pollen extracts either of birch or combinations of alder, birch and hazel
78. Effects of birch pollen-specific immunotherapy on apple allergy in birch pollen-hypersensitive patients
79. What are the important allergens in grass pollen that are linked to human allergic disease?
80. cDNA cloning of the major allergen Phl p I from timothy grass (Phleum pratense); recombinant Phl p I inhibits IgE-binding to group I allergens from eight different grass species
81. Molecular, immunological, and structural characterization of Phl p 6, a major allergen and p-particle associated protein from timothy grass (Phleum pratense) pollen